Skip to main content
Premium Trial:

Request an Annual Quote

MDS Extends Offer to Buy Molecular Devices to Meet Foreign Regulations

NEW YORK (GenomeWeb News) – MDS has extended to March 19 its offer to buy Molecular Devices in order to give it additional time to meet “certain foreign regulatory conditions,” MDS said today.

The company still expects the deal to close within the next few weeks. It is in the process of meeting regulatory requirements in and in , MDS spokesperson Catherine Melville told GenomeWeb News.  

As GenomeWeb News previously in January, the companies had agreed to a deal under which MDS would buy Molecular Devices for $615 million in cash, or $35.50 a share for all of Molecular Devices’ common stock.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.